ASCO Annual Meeting | Conference

Dr. Chi on the TITAN Trial Results in Metastatic Castration-Sensitive Prostate Cancer

June 2nd 2019

Kim N. Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the results of the phase III TITAN trial, which evaluated apalutamide versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Dr. Tripathy Discusses the MONALEESA-7 Trial in HR+ Breast Cancer

June 2nd 2019

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the MONALEESA-7 trial in hormone receptor-positive breast cancer.

Open Source System Debuts for EHR Data Sharing

June 2nd 2019

A consortium of cancer care institutions released details on a prototype system designed to link electronic health record systems to provide a source of real-world patient information to guide research and improve cancer treatment.

New Strategies Needed for TKI Resistance in EGFR+ Lung Cancer

June 1st 2019

The development of tyrosine kinase inhibitors has revolutionized the treatment of EGFR-mutant non–small cell lung cancer in recent years, but new strategies are needed to overcome resistance mechanisms that promote disease recurrence.

Apalutamide Extends Survival in Metastatic Castration-Sensitive Prostate Cancer

June 1st 2019

Adding apalutamide to androgen deprivation therapy (ADT) reduced the risk of the death by 33% in patients with metastatic castration-sensitive prostate cancer compared with ADT alone.

Frontline Pembrolizumab Induces Comparable OS, Fewer AEs in Advanced GEJ Cancer

June 1st 2019

Frontline pembrolizumab demonstrated non-inferior overall survival compared with standard chemotherapy among patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.

Ribociclib Improves Survival by Nearly 30% for Premenopausal Women With Advanced Breast Cancer

June 1st 2019

Ribociclib plus endocrine therapy demonstrated an estimated overall survival rate of 70.2% at 42 months compared 46.0% for placebo and endocrine therapy in premenopausal women with HR-positive, HER2-negative advanced breast cancer.

Pembrolizumab OS Rates Continue to Impress in NSCLC at 5 Years

June 1st 2019

After 5 years, newly diagnosed patients with advanced non–small cell lung cancer demonstrated an overall survival (OS) rate of 23.2% from treatment with pembrolizumab monotherapy and previously treated patients had an OS rate of 15.5%.

Dr. Goy on CAR T-Cell Therapy Updates in Non-Hodgkin Lymphoma

June 1st 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.

Dr. Agarwal on the TALAPRO-2 Trial in mCRPC

June 1st 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses part 1 findings from the phase III TALAPRO-2 trial in metastatic castration-resistant prostate cancer.

ASCO 2019: Oncology Leaders Select Top Studies

May 29th 2019

Within the week, thousands of abstracts spanning a multitude of tumor types will be presented at the 2019 ASCO Annual Meeting, many of which will lead to practice-changing implications for oncologists.

Entrectinib Achieves Strong Responses in Pediatric Cancers, Including CNS Tumors

May 16th 2019

Entrectinib induced objective responses in 100% of pediatric patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions or mutations.

Pediatric Precision Medicine Approach Proven Possible in Pediatric MATCH Trial

May 16th 2019

About a quarter of pediatric patients with cancer were able to be screened for targetable alterations in their tumor and directed to a treatment targeting that alteration of pathway in the screening protocol of the National Cancer Institute-Children’s Oncology Group Pediatric MATCH trial.

Lower-Dose Chemotherapy Regimen Benefits Elderly, Frail Patients with Gastroesophageal Cancer

May 16th 2019

A lower dose of oxaliplatin and capecitabine had comparable efficacy and minimized adverse events in elderly and frail patients with advanced gastroesophageal cancer.

Lenalidomide Reduces Risk for Smoldering Multiple Myeloma Progression

May 16th 2019

In patients with smoldering multiple myeloma, lenalidomide induced a 72% reduction in the risk for progression to symptomatic disease at 3 years.

Low-Fat Diet Could Reduce Risk of Death From Breast Cancer

May 16th 2019

Women who eat a balanced, low-fat diet and daily portions of vegetables, fruit, and grains have a 21% lower risk of dying from breast cancer.

Dr. Gupta on Impact of Pembrolizumab Plus Bevacizumab Findings in RCC

July 10th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the impact of the phase Ib/II results of pembrolizumab (Keytruda) plus bevacizumab (Avastin) in patients with metastatic renal cell carcinoma.

Dr. Tewari on the Promise of Immunotherapy in Cervical Cancer

July 10th 2018

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the promise of immunotherapy in cervical cancer.

Dr. Abramson Discusses Lisocabtagene Maraleucel in NHL

July 10th 2018

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses lisocabtagene maraleucel (JCAR017; liso-cel) as a treatment for patients with non-Hodgkin lymphoma.

Dr. Iwata Discusses DS-8201a in HER2+ Breast Cancer

July 10th 2018

Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses DS-8201a in HER2-positive breast cancer.